NYU Langone Orthopedic Hospital, New York, New York, U.S.A..
NYU Langone Orthopedic Hospital, New York, New York, U.S.A.
Arthroscopy. 2020 May;36(5):1345-1352. doi: 10.1016/j.arthro.2020.01.017. Epub 2020 Feb 6.
To evaluate postoperative outcomes and preoperative risk factors for patients with underlying systemic inflammatory disorders after hip arthroscopy.
A retrospective analysis of patients who had undergone hip arthroscopy, with a history of systemic inflammatory disease, was performed. This included patients with a diagnosis of lupus, a positive antinuclear antibody test, rheumatoid arthritis, psoriatic arthritis, sarcoidosis, inflammatory bowel disease, Reiter syndrome, and mixed connective tissue disease. These cases were 1:2 matched to a control group of patients with no history of systemic inflammatory disease based on age and sex. An a priori power analysis was conducted and A 1:2 case-control ratio was selected to increase study power. Inclusion criteria included all skeletally mature patients with hip pain refractory to nonoperative management who underwent hip arthroscopy for labral tears and femoroacetabular impingement. Skeletally immature patients, those with Tönnis grades of 2 or more (less than 2 mm of joint space), hip dysplasia, patients undergoing revision hip arthroscopy, and patients whose pain failed to improve after intra-articular injection were excluded. The primary outcome was rate of revision hip arthroscopy or total hip arthroplasty 24 months after surgery. Secondary outcomes included 2 patient-reported outcome scores, the modified Harris Hip Score (mHHS) and Non-Arthritic Hip Score (NAHS).
Twenty patients (21 hip arthroscopy procedures) and 42 controls were included. There was no significant difference in proportion of patients who met failure criteria (28.6% vs 16.7%, P = .271) or 2-year survivorship (76.2% vs 83.3%, P = .496) between the systemic inflammatory disorder and control groups, respectively. Both groups had a significant improvement in mHHS and NAHS at 24 months compared with baseline; however, there was no significant difference in mHHS (P = .28) or NAHS (P = .22) at 24 months between the 2 groups.
Patients with underlying inflammatory conditions have similar 2-year outcomes after hip arthroscopy for intra-articular pathology compared with patients with no history of inflammatory disease.
III, retrospective comparative study.
评估髋关节镜检查术后患有潜在系统性炎症性疾病患者的术后结果和术前危险因素。
对曾患有系统性炎症性疾病(包括狼疮、抗核抗体阳性、类风湿关节炎、银屑病关节炎、结节病、炎症性肠病、赖特综合征和混合性结缔组织病)并接受髋关节镜检查的患者进行回顾性分析。这些病例根据年龄和性别与无系统性炎症性疾病史的对照组患者进行 1:2 匹配。进行了事先的功效分析,并选择了 1:2 的病例对照比以提高研究效力。纳入标准包括所有因髋关节疼痛经非手术治疗无效而接受髋关节镜检查治疗盂唇撕裂和股骨髋臼撞击症的骨骼成熟患者。排除骨骼未成熟患者、Tönnis 分级为 2 级或更高(关节间隙小于 2 毫米)、髋关节发育不良患者、接受髋关节镜翻修手术的患者以及关节内注射后疼痛未改善的患者。主要结局是术后 24 个月时行髋关节翻修术或全髋关节置换术的比率。次要结局包括 2 项患者报告的结局评分,改良 Harris 髋关节评分(mHHS)和非关节炎髋关节评分(NAHS)。
共纳入 20 例患者(21 例髋关节镜手术)和 42 例对照。在符合失败标准的患者比例(28.6%比 16.7%,P=0.271)或 2 年生存率(76.2%比 83.3%,P=0.496)方面,炎症性疾病组和对照组之间无显著差异。两组患者 mHHS 和 NAHS 在术后 24 个月与基线相比均有显著改善;然而,两组在 mHHS(P=0.28)或 NAHS(P=0.22)方面在术后 24 个月时无显著差异。
患有潜在炎症性疾病的患者在髋关节镜检查治疗关节内病变后 2 年的结果与无炎症性疾病史的患者相似。
III 级,回顾性比较研究。